The association of centromere amplification and response to trastuzumab in HER2+metastatic breast cancer

被引：0
|
作者：
Andrieu, Charlotte
Al-Sultan, Dalal
Ivers, Laura
Pina, Jose Javier Berenguer
Skrobo, Darko
Ballot, Josephine
Eustace, Alex J.
Gullo, Giuseppe
Crown, John
机构：
[1] Dublin City Univ, Sch Biotechnol, Natl Inst Cellular Biotechnol, Dublin, Ireland
[2] St Vincents Univ Hosp, Dept Med Oncol, Dublin, Ireland
[3] CCRT Caroline Fdn, Dublin, Ireland
[4] Galway Univ Hosp, Dept Histopathol, Galway, Ireland
[5] St Vincents Univ Hosp, Dept Med Oncol, Dublin, Ireland
[6] St Vincents Univ Hosp, Dept Pathol, Dublin, Ireland
[7] Regeneron Pharmaceut Inc, Tarrytown, NY USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1016
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Bevacizumab plus trastuzumab for treatment of HER2+metastatic breast cancer
    De Amuriza Chicharro, N.
    Gastalver Martin, C.
    Goyache Goni, M. P.
    Cortijo Cascajares, S.
    Garcia Munoz, C.
    Ferrari Piquero, J. M.
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2013, 35 (05) : 984 - 985
  • [2] Study of the combination gemcitabine and trastuzumab in the treatment of HER2+metastatic breast cancer
    Menjon-Beltran, S.
    Olivencia-Dueso, R.
    Gonzalez-Jimenez, E.
    Titos, M. J.
    BREAST CANCER RESEARCH, 2007, 9 (01)
  • [3] Systemic toxicities of trastuzumab-emtansine predict tumor response in HER2+metastatic breast cancer
    Tang, Shou-Ching
    Capra, Carter Louis
    Ajebo, Germame H.
    Mairs, Simon
    Meza-Junco, Judith
    Hillegass, William B.
    Craft, Barbara S.
    Zhu, Xiaofu
    CANCER RESEARCH, 2020, 80 (04)
  • [4] Systemic toxicities of trastuzumab-emtansine predict tumor response in HER2+metastatic breast cancer
    Tang, Shou-Ching
    Capra, Carter L.
    Ajebo, Germame H.
    Meza-Junco, Judith
    Mairs, Simon
    Craft, Barbara S.
    Zhu, Xiaofu
    Maihle, Nita
    Hillegass, William B.
    INTERNATIONAL JOURNAL OF CANCER, 2021, 149 (04) : 909 - 916
  • [5] Use and safety of trastuzumab emtansin in HER2+metastatic breast cancer in a tertiary hospital
    Chaguaceda Galisteo, C.
    Manzaneque Gordon, Alba
    Del Rio Torres, Hector Jose
    Baro, Natalia Creus
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2017, 39 (01) : 286 - 286
  • [6] Trastuzumab for HER2+metastatic breast cancer in clinical practice: Cardiotoxicity and overall survival
    Rossi, Marta
    Carioli, Greta
    Bonifazi, Martina
    Zambelli, Alberto
    Franchi, Matteo
    Moja, Lorenzo
    Zambon, Antonella
    Corrao, Giovanni
    La Vecchia, Carlo
    Zocchetti, Carlo
    Negri, Eva
    EUROPEAN JOURNAL OF CANCER, 2016, 52 : 41 - 49
  • [7] Predictors of survival in patients with HER2+metastatic breast cancer (MBC) treated with trastuzumab
    Olson, E. M.
    Najita, J. S.
    Sohl, J.
    Arnaout, A.
    Winer, E. P.
    Lin, N. U.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [8] COST-EFFECTIVENESS ANALYSIS OF TRASTUZUMAB DERUXTECAN FOR PATIENTS WITH HER2+METASTATIC BREAST CANCER
    Mudumba, R.
    Chan, H.
    Cheng, Y. Y.
    Wang, C. C.
    Correia, L.
    Ballreich, J.
    Levy, J.
    VALUE IN HEALTH, 2022, 25 (12) : S95 - S95
  • [9] Trastuzumab emtansine, an antibody-drug conjugate for the treatment of HER2+metastatic breast cancer
    Niculescu-Duvaz, Ion
    CURRENT OPINION IN MOLECULAR THERAPEUTICS, 2010, 12 (03) : 350 - 360
  • [10] Trastuzumab and vinorelbine or taxane chemotherapy for HER2+metastatic breast cancer: The TRAVIOTA study.
    Burstein, H. J.
    Keshaviah, A.
    Baron, A.
    Hart, R.
    Lambert-Falls, R.
    Marcom, P. K.
    Gelman, R.
    Winer, E. P.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 40S - 40S
12345